Nevanimibe is an orally active and selective inhibitor of acyl-coenzyme A:cholesterol O-acyltransferase 1 (ACAT1) (EC50 of 9 nM).

In H295R human adrenocortical carcinoma cells, Nevanimibe(ATR-101) decreases the formation of cholesteryl esters and increases FC levels, demonstrating potent inhibition of ACAT1 activity.?Caspase-3/7 levels and terminal deoxynucleotidyl transferase 2'-deoxyuridine 5'-triphosphate nick end labeled-positive cells are increased by ATR-101 treatment, indicating activation of apoptosis[1].

133825-80-6

C27H39N3O

421.62

ATR-101;PD-132301;Nevanimibe

(< 1 mg/ml refers to the product slightly soluble or insoluble )
Powder: -20°C for 3 years
In solvent: -80°C for 2 years